Loading patent…
AssigneeUniversitätsklinikum Hamburg-Eppendorf
InventorsManuel Friese, Benjamin Schattling, Karin Steinbach, Marc Freichel, Veit Flockerzi, Rudi Vennekens, Doron Merkler
Estimating the term…
The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.
A method of treating Multiple Sclerosis in a subject, comprising administering to a subject that suffers from Multiple Sclerosis a therapeutically effective amount of a compound which is effective in inhibiting the function of a TRPM4 ion channel and inhibits or reduces axonal injury in the subject.
A method of treating Multiple Sclerosis in a subject, comprising administering to a subject that suffers from Multiple Sclerosis a pharmaceutical composition comprising a therapeutically effective amount of a compound which is effective in inhibiting the function of a TRPM4 ion channel and inhibits or reduces axonal injury in the subject.
In vitro method for identifying a pharmaceutically active compound for treating or preventing a neurodegenerative disease in a subject, comprising:
A polypeptide comprising the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2 or a variant thereof having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:2;
Dependencies are inferred from the claim text.